Ordering
Available Variants5 mg
CHA.18866-5mg
Price
€64.08
Available – Dispatch in 14 days
25 mg
CHA.18866-25mg
Price
€258.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.18866-5mg | €64.08 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.18866-25mg | €258.40 |
≥95% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C34H46ClN3O10 |
|---|---|
| CAS Number | 35846-53-8 |
| Molecular Weight | 692.20 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD28127038 |
| Assay | ≥95% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS08
 GHS08
|
|---|---|
| signalword | Danger |
| hcodes | H341,H361d,H372 |
| pcodes | P202 - P260 - P264 - P270 - P280 - P308 + P313 |
| Hazard Classifications | Muta. 2 - Repr. 2 - STOT RE 1 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Maytansine, with a CAS number of 35846-53-8, is a potent ansamycin antibiotic that has been isolated from the bacterium Nocardia spp. and the actinomycete Actinosynnema pretiosum. It exhibits strong cytotoxic activity against various cancer cell lines, making it a subject of interest in cancer research. Maytansines mechanism of action involves the inhibition of microtubule assembly, thereby disrupting cell division and ultimately leading to cell death. Due to its high potency and potential for use in targeted cancer therapies, maytansine has been conjugated to monoclonal antibodies to create antibody-drug conjugates, which aim to deliver the cytotoxic agent directly to cancer cells while minimizing harm to healthy tissues. This approach has shown promise in preclinical and clinical trials, highlighting maytansines potential as a valuable component in the development of novel cancer treatments.
